-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $81 Price Target

Benzinga·07/08/2025 10:55:02
Listen to the news
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $81 price target.